On this episode of Biotalk, Locust Walk‘s Daniel Brog welcomes with Shehnaaz Suliman, M.D., CEO of ReCode Therapeutics, a clinical-stage genetic medicines company using its […]
On this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes Errik Anderson, CEO and Founder of Alloy Therapeutics, to the podcast. Alloy is a trailblazing
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, delves into our 2023 Q3 Report: Global Trends in Biopharma Transactions Report.
On this episode of Biotalk, Locust Walk‘s Andy Meyerson welcomes Helen Ho, Chief Business Officer of Blueprint Medicines, to the podcast. Blueprint Medicines is a
On this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes Howard Federoff, MD PhD, Scientific Co-Founder, Chief Medical Officer, and Director of Ryne Biotechnology, to the
On this episode of Biotalk, Locust Walk’s Andy Meyerson welcomes Jason Kelly, co-Founder and CEO of Ginkgo Bioworks, to the podcast. Ginkgo Bioworks is at
On this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes Onaiza Cadoret-Manier, Executive Vice President, Chief Global Product Strategy & Operations Officer at Ionis Pharmaceuticals to
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2023 Q2 Report: Global Trends in Biopharma Transactions Report. Each
Podcast: Play in new window | Download (Duration: 11:08 — 12.2MB)
Subscribe: Apple Podcasts | Spotify | RSS
This episode of Biotalk is focused on Locust Walk’s 2023 First Quarter Market Conditions Report, in which we apply the latest
Podcast: Play in new window | Download (Duration: 41:12 — 45.4MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Locust Walk welcomes Andrew Allen, M.D., Ph.D., Co-Founder, President, CEO, and board member of Gritstone